COSCIENS Biopharma Inc. (CSCI.TO)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 4 | 5 | 15 | 4 | 10 | 8 | 8 | - |
| Operating profit | $m | -11 | -5 | ||||||
| Net profit | $m | 1 | 3 | 3 | -4 | -15 | -11 | -5 | - |
| EPS reported | $ | -29.97 | -13.03 | ||||||
| Operating cashflow per share | $ | -24.51 | -3.52 | ||||||
| Capex per share | $ | 2.04 | 0.04 | ||||||
| FCF per share | $ | -26.56 | -3.57 | ||||||
| Free cash flow | $m | -9 | -4 | ||||||
| Net debt | $m | -7 | -3 | ||||||
| Book value equity | $m | 4 | 15 | ||||||
| Book value per share | $ | 10.90 | 14.15 | ||||||
| Number of shares | m | 0.35 | 1.05 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.57 | 0.15 | ||||||
| P/S LTM | x | 0.29 | 0.27 | ||||||
| P/FCF LTM | x | -0.23 | -0.58 | ||||||
| EV/EBITDA LTM | x | 0.32 | 0.84 | ||||||
| EV/Sales LTM | x | -0.39 | 0.34 | ||||||
| Earnings Yield LTM | % | -4.83% | -79.22% | ||||||
| FCF Yield | % | -428.03% | -171.21% | ||||||
| Quality | |||||||||
| ROE | % | -274.82% | -48.52% | ||||||
| ROIC | % | -59.02% | -28.55% | ||||||
| Operating margin | % | -1.39% | -58.56% | ||||||
| Gross margin | % | +35.30% | +45.30% | ||||||
| FCF/Sales | % | -122.42% | -45.69% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -20.42% | -14.71% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -4.35 | -1.91 | ||||||
| Net Debt/EBITDA | x | 0.55 | 0.93 | ||||||
| EBIT/Net interest | x | -62.15 | -28.19 | ||||||
| Net debt/market cap | % | +9.84% | +3.08% | ||||||
| Net debt/Equity | x | -1.85 | -0.22 | ||||||
| Gross debt/equity | x | 0.56 | 0.13 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally active peptidomimetic small molecule that stimulates the secretion of growth hormone from the pituitary gland. The company sells its products through its distribution network. It has license agreements with Pharmanovia, Davimed GmbH, and NK MEDITECH Ltd, as well as Agriculture Canada, Canadian Government, and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally active peptidomimetic small molecule that stimulates the secretion of growth hormone from the pituitary gland. The company sells its products through its distribution network. It has license agreements with Pharmanovia, Davimed GmbH, and NK MEDITECH Ltd, as well as Agriculture Canada, Canadian Government, and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free